Status:
In progress
Technology type:
Medicine
Decision:
Selected
Reason for decision:
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process:
STA Standard
ID number:
6403

Project Team

Project lead
Jennifer Upton

Email enquiries

If you have any queries please email TACommA@nice.org.uk


External Assessment Group:
BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors
GlaxoSmithKline (niraparib)
Others
Department of Health and Social Care
 
NHS England
Patient carer groups
Ovacome
 
Ovarian Cancer Action
Professional groups
Association of Cancer Physicians
 
Cancer Research UK
 
Royal College of Physicians
 
Royal College of Radiologists
Comparator companies
AstraZeneca
General commentators
All Wales Therapeutics and Toxicology Centre
 
British National Formulary
 
Department of Health, Social Services and Public Safety for Northern Ireland
 
Healthcare Improvement Scotland
 
Medicines and Healthcare products Regulatory Agency
 
NHS Wales Joint Commissioning Committee
 
Scottish Medicines Consortium
 
Welsh Government
Relevant research groups
Institute of Cancer Research
 
National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
02 December 2025 Committee meeting
12 May 2025 Invitation to participate
12 May 2025 In progress. Invitation to participate
12 May 2025 In progress. Invitation to participate
14 March 2025 - 11 April 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 January 2025 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual